ÿþ
|
|
|
- ゆみか かに
- 5 years ago
- Views:
Transcription
1 YV-18 YV-19 YV-20 HALS Surgrx Enseal System :10 17: YP-1 YP-2 YP-3 YP-4 YP-5 YP TS :10 17: YP-7 YP-8 YP-9 YP-10 YP-11 YP-12 1 IPMN Gemcitabine :10 17: YP
2 YP-14 YP-15 YP YP :55 16: YP-18 YP-19 YP YP-21 YP :55 16: YP-23 1 YP-24 YP-25 YP-26 YP-27 Stage IVa PD 10 1 TACE TS1 YP :55 16: YP
3 YP-30 YP-31 YP-32 YP-33 YP CA :10 17: YP-35 YP-36 YP-37 YP-38 YP-39 Paclitaxel HbsMPC polymer SNP FGFR fibroblast growth factor receptor :10 17: YP-40 YP-41 YP-42 YP-43 YP-44 YP-52 hepcidin Methionine adenosyltransferase A2 discarded marginal donors rescue Magnetic Resonance Imaging
4 :55 16: YP-45 YP-46 YP-47 Cap43/NDRG1 YP-48 NOMI 2 YP :55 16:55 2 YP-50 S100A4 YP-51 High-mobility group protein HMGB 1 YP-53 YP-54 CD4+CD25+FoxP3+ T CT :10 17: YP-55 C IFN SVR 6 YP-56 YP-57 YP-58 B C HCV YP-59 YP-60 ROC 2 YP
5 :10 17: YP-62 YP-63 YP-64 YP-65 YP-66 YP-67 YP-68 ADAMTS13UL-VWFM HMGB-1 RAGE TissueLink monopolar devise TM P-107 Transjugular intrahepatic portsystemic shunt TIPS :10 17: YP-69 YP-70 YP-71 YP-72 YP-73 YP-74 CPT-11+S-1 II LC MCN IPMN :55 16: YP-75 YP-76 YP-77 KL-6 MUC1 KL-62 Fascin PET/CT
6 YP-78 YP-79 YP-80 FDG-PET/CT ICG PDE TS :55 16: YP-81 YP-82 immunonutrition YP-83 YP-84 YP :55 16: YP-86 YP-87 Gemcitabine+CDDP GC YP-88 YP-89 TS :55 16: YP-90 ERCP YP-91 YP-92 YP-93 CD44 YP-94 Na + /H + exchanger FR
7 :10 17: P-1 HCC P-2 P-3 RFA P-4 P-5 2cm P-6 P :10 17: P-8 P-9 P-10 P-11 IFN 1 P-12 C 151 P-13 1 P-14 1HCC :10 17: P-15 ITP 1 P
8 P-17 1 P-18 P-19 C SVR 10 1 P-20 1 P :10 17: P-22 C 3cm P-24 Belghiti s liver hanging maneuver3 P-25 1 P-26 1 P-27 1 P-28 P :10 17: P-30 AFP 1 P-31 1 P-32 1 P-33 P-34 P-35 B
9 :10 17: P-36 1 P-37 1 P-38 IFNSVRC3 P-39 B P-40 P :10 17: P-42 1 P-43 1 P-44 2 P-45 1 P-46 P :10 17: P-48 P-49 2 P-50 S 1 P
10 P-52 Degradable Starch Microsphere 3 P :10 17: P-54 1 P-55 P-56 3 S 1 P-57 P-58 TEM 1 P :10 17: P-60 P-61 S 1 P-62 P-63 1 P-64 P :10 17: P-66 H3 P-67 sm 3 P
11 P-69 P-70, :10 17: P-71 1 P-72 P-73 1 P-74 1 P-75 P :55 16: P-77 CA19-9 P-78 1 P-79 PET granulomatous abscess 1 P-80 1 P-81 Peliosis hepatis :55 16:55 2 P-82 1 P-83 P-84 P
12 P-86 inflammatory pseudotumor 3 P :55 16:55 1 P-90 Danaparoid sodium P-91 2 P P :55 16:55 P-94 PTPE P P-96 Tc-99m-GSA 1 P-97 P-98 longitudinal spread MDCT cholangiography direct cholangiography :55 16:55 P-99 volumetry PTPE P P-101 SPECT-CT fusion P P-103 Vv3 out.ow block
13 P-104 Microwave coagulation :55 16:55 P-105 S4 S5 S8 1 P P-108 P P-110 IVR IIIb 1 P :55 16:55 P-112 P-113 P-114 FNH: Focal nodular hyperplasia 1 P P P :55 16:55 P-118 VAHS P-119 P P
14 P-122 PSC 2 P-123 B ABO 1 P :55 16:55 SSI NTT P-125 P-126 P-127 P-128 SSI P-129 SSI NTT :55 16:55 P-130 NST P-131 immunonutrition P-132 P-133 DPC P :55 16:55 P P-136 P-137 CR 1 P
15 P-139 RFA 1 P-140 P :55 16:55 P P-143 PTCD 1 P P-145 C 1 P-146 P :55 16:55 P P-149 P-150 A 1 P-151 SLE 1 P P-153 NASH :10 17:10 1 P-154 B4 P
16 P-156 peribiliary cyst P P-158 IPNB 2 JA :10 17:10 2 P-159 IPNB 1 P P P P-163 intraductal oncocytic papillary carcinoma :10 17:10 P-164 A2 A3 A4 1 P P-166 SMA HPD 1 P P P-169 P :10 17:10 1 P-171 C 2 P
17 P-173 P-174 P-175 P :10 17:10 2 P P PTBD 1 P-180 P P-182 A Case of Solitary Liver Metastasis from Bile Duct Carcinoma P-183 P :10 17:10 1 P P-186 P-187 P-188 P-189 P-190 P
18 :10 17: P-192 P P-194 pitfall P P-196 P-197 PET/CT 2 P P :10 17: P P-201 Malignant fibrous histiocytoma P P P P-205 IPMN 1 P :10 17:10 1 P-207 #16 1 P
19 P-209 Virchow 2 3 P P-211 P-212 P :10 17:10 2 P-214 EMA1 P P P P-218 P P :10 17:10 1 P-221 P-222 P-223 P-224 P-225 P P
20 :10 17: P-228 P-229 P-230 P P :10 17: P P-235 P-236 P-237 P :10 17: P P-240 P-241 m 5 P-242 P-243 P-244 Vibrio cholerae non
21 :55 16: P P P P-248 P-249 P :55 16: P-251 P P P P P :55 16:55 2 P P-258 Lemmel P-259 Lemmel 2 P P
22 P-262 P :55 16:55 P-264 P-265 Mirizzi 1 P-266 P-267 Biliary ablation 1 P P-269 Retrograde transhepatic biliary drainage PTBD :55 16:55 P-270 P P P P P-275 Angio-CT P-276 IgG4 1 P-277 IgG :55 16:55 P
23 P P-280 P P P-283 choledochocele 1 P-284 P :55 16:55 P P-287 Mirizzi 1 P-288 Mirizzi 6 P-289 Bouveret's syndrome P P P :55 16:55 Vater 1 P-293 P-294 P-295 P
24 P-297 Vater 1 2 P P :55 16:55 Vater 2-1 P P P P P :55 16:55 Vater 2-2 P-305 P-306 P P P :55 16:55 P-310 long SD P-311 Gemcitabine JA P-312 Stage4b TS-1 P-313 Gemcitabine
25 P-314 GEM /CAP P-315 gemcitabine :10 17:10 P-316 FDG-PET/CT P-317 FDG-PET P-318 FDG-PET P-319 diffusion weighted imaging ; DWI P-320 P :10 17:10 1 P-322 P-323 P-324 pn0 P-325 P-326 P :10 17:10 1 P P-329 TS11 P
26 P P-332 MDCT 1 P-333 Stage IVa :10 17:10 2 P P Stage IVb P-336 S-11 JA P P P-339 pancreatic acinar cell carcinoma :10 17:10 3 P-340 Groove 1 P-341 TS1 P P P-344 PanINs P P :10 17:10 3 P
27 P P-349 JA P-350 duct-islet cell carcinoma 1 P P :10 17:10 IPMN1-1 P-353 IPMN P-354 P-355 IPMN P-356 IPMN P-357 IPMN P P-359 IPMN :10 17:10 IPMN1-2 P-360 IPMN 3 P-361 IPMN 2 P-362 IPMT 8 P P-364 IPMN 2 P-365 IPMN P-366 GIST IPMT
28 :10 17:10 IPMN2 P P P-369 IPMN P P P-372 IPNM P P-374 MCN :10 17:10 1 P-375 PD DGEPPPD SSPPD P-376 P-377 P-378 P-379 J-VAC P-380 T P :10 17:10 1 P-382 PD P
29 P-384 CEZ CTM P-385 P P :10 17: P-388 P-389 Appleby1 P-390 P P-392 P :10 17: P-394 P-395 P P-397 Appleby P
30 :55 16:55 P-399 P-400 PpPD P P-402 P-403 PpPD P :55 16:55 1 P-405 P IVR 1 P-407 P P P :55 16:55 2 P P P-413 P-414 P
31 P-416 ASVS :55 16:55 3 P P-418 P P P-421 MEN :55 16:55 P P P P P P :55 16:55 P P-429 IPACC P-430 P P
32 P-433 solid pseudopapillary tumor SPT 2 P solid pseudopapillary tumor :55 16:55 1 P-435 Dermoid cyst P P P P P-440 solid pseudopapillary tumor 1 P :55 16:55 2 P-442 solid pseudopapillay tumor 1 P P-444 lymphoepithelial cyst 1 P-445 Dermoid cyst 1 P-446 lymphoepithelial cysts :55 16:55 P P P-449 IPMT lymphoepithelial cyst
33 P P P-452 P :55 16:55 P P-455 MCN 1 P-456 P-457 WDHA VIP 1 P-458 MALT 1 P-459 FNH P :55 16:55 P P-462 P-463 IgG4 1 P C P-465 P-466 TAE
34 :55 16:55 P-467 P-468 Lymphoplasmacytic sclerosing pancratitis P P-470 P-471 P P :55 16:55 P-474 TS-1 P-475 RAD001 gemcitabine P-476 CD-DST P FU+CDDP1 P-478 Gemcitabine Oxaliplatin GemOx CR P-479 Gemcitabine GEM1 P-480 Gemcitabine + S :10 17:10 NET GIST P P-482 Large cell neuroendocrine carcinoma 1 P
35 P-484 GIST P-485 GIST :10 17:10 NET GIST P-486 gastrointestinal stromal tumor GIST P P-488 P-489 P :55 16:55 P P P P-494 P mm x 38mm Brunner :55 16:55 P P-497 P P
22肝胆膵_抄録_1_ indd
001 5 26 11:30 12:30 9-1 PO001-1 PO001-2 I II 2cm MRI PO001-3 PO001-4 PO001-5 PO001-6 5cm (Vp3/4,Vv2/3) PO001-7 1 PO001-8 B HCC C HCC B HCC PO001-9 002 5 26 11:30 12:30 9-1 PO002-1 HDAC PO002-2 Down Staging
全国循環器撮影研究会 HP講座No
HP No.6 4 HP No.6 4 NTT 1. 1936 1953 Seldinger Seldinger 1956 Odman X Interventional Radiology IVR 1967 Margulis 1964 Dotter 2. 2.1 IVR CT MR IVR 2.2-1 - HP No.6 4 2.3 feeding artery parasitic supply increased
膵癌超音波診(案)
1 2 3 4 5 6 7 8 9 10 2009 7 6 2 a. invasive ductal carcinoma * 1 b. endocrine neoplasm c. Solid pseudopapillary neoplasm d. tumor producing pancreatitis * 2 * 1 invasive ductal carcinomas papillary adenocarcinoma
評価結果報告書の概要版（平成20年度）
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76
44-1(前11)7回春季大会
PET 5 18 5 20 5 18 5 20 5 18 5 20 5 18 5 20 5 18 17:10 18:35 19 5 18 20 URL: http://www.t-inform.co.jp/jsnm-s7/ 7 http://www.t-inform.co.jp/jsnm-s7/ 7 19 5 18 20 7 7 PET PET PET RI 2 19 PET PET PET 1
がん診療におけるFDG FDG-PET/CTの役割
PET/CT PET/CT MRI PET PET/CT Kurashiki Central Hospital FDG-PET CT PET/CT (stage1) FDG-PET (stage1) PET/CT FDG-PET PET/CT (stage4) FDG-PET (stage4) PET/CT FDG-PET PET/CT PET/CT
日本消化器外科学会教育集会
200214 IPMT MCT 15 90 2000 6.5 1 Epithelial tumors Exocrine tumors Serous cystic tumors Mucinous cystic tumors Intraductal tumors Atypical hyperplasica(ah)and carcinoma in situ(cis) Invasive ductal carcinoma
11 第25回がん学会一般演題一覧（第3会場）
1) 2) 1) 2) KTSND 2 200 KTSND KTSND 2014 4 CD56 Chromogranin Ki67 70% CT T2N4M0stage IVa /(egfr 55ml/min Cre 1.05mg/dl)/ PR 12 2015 4 CT 6 62 20XX 6 CTMRI 5 7 10 DIC methotrexatemtx /5-FU DIC score ALP
原著・報告・記録（４４行）／Ｐ１３４～１４７＿報告 肝移植症例登録
134 Vol. 52, No. 23 Liver transplantation in Japan. Registry by the Japanese Liver Transplantation Society The Japanese Liver Transplantation Society Summary As of December 31, 2016, a total of 8,825 liver
02-06プ_一般ポスター_0407.indd
一般ポスター工学基礎一般ポスター工学基礎 イメージング 信号処理 5 月 7 日 ( 土 )6:0-7:0 ポスター 展示会場 座長 : ( 栃木県総合文化センター 階第 4 ギャラリー ) 90- 基 P-00 CT S6 90- 基 P-00 S6 90- 基 P-00 S6 90- 基 P-004 S6 90- 基 P-005 S64 90- 基 P-006 S64 90- 基 P-007 STC
IVR232.indb
IVR Jpn J Intervent Radiol 23, 2008. 1 1 71 2 1 3D CTA DSA direct CCF 5 1CCF CCF 3D CTA 24 17/70 1999 1999 5 2004 12 92 83 76/92 1 1.3 1/76 93 71/76 1 1.3 1/76 370 CT 3 1 C3 2 C6 3 C5 1 1 1 546 2 1 2 3
092_41-1_23九州CS6_責.indd
2013 10 6 1, 2 3 4, 5, 4, 6, 3, 5, 1, 1 1, 2, 3, 4, 5, 6,70. 2011 7 CT, B C, -GTP,CEA CA 19-9.US,S 2 / 3 43 37 mm,. 11 mm,,.ceus,.,.,. 1, 1, 1, 1, 1, 1, 1, 1, 1, 2 1, 2 52. S 7 20 mm,. CT, CT, EOB MRI,T
97_shigeo-nakayama-j.PDF
114 114 6240 900-1- 4 2 1 5 2 5 12-2- 1 2 2 24 3 2 7 9 1 15 7 9 4 4 1 7 160-3- -4-1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 1 20 25 5 1 2 3 4 5 6 45m 30m 3m 24 1 3 6 1 2 12 3 4
原著・報告・記録（４４行）／Ｐ１５６～１６９＿報告 肝移植症例登録
156 Vol. 50, No. 23 Liver Transplantation in Japan Registry by the Japanese Liver Transplantation Society The Japanese Liver Transplantation Society Summary As of December 31, 2014, a total of 7,937 liver
Microsoft Word 年度DPCによるSPECT検査動向に関する報告 _02表紙.doc
DPC SPECT 2 2013 9 DPC/PDPSDiagnosis Procedure Combination / Per-Diem Payment System 1 DPC DRG/PPS: Diagnosis Related Groups / Prospective Payment System 2003 2008 7 2008 DPC 2012 1,500 DPC SPECT 70% DPC
原著・報告・記録（４４行）／Ｐ１４５～１５９＿報告 肝移植症例登録
145 Liver Transplantation in Japan Registry by the Japanese Liver Transplantation Society The Japanese Liver Transplantation Society Summary As of December 31, 2015, a total of 8,387 liver transplants
原著・報告・記録（４４行）／Ｐ２６１～２７４＿報告 肝移植症例登録
261 Liver Transplantation in Japan Registry by the Japanese Liver Transplantation Society The Japanese Liver Transplantation Society Summary As of December 31, 2013, a total of 7,474 liver transplants
₂₈ TFT 1 ₁ ₁ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B-Flow,., B-Flow B Flow. 2, , 2, 3.,,. Logiq S8 GE. ₁ ₂ 1, 1, 1, 1, 2, 3, 3, 3
₂₈ 2016 10 22 23 TFT 1 ₁ ₁ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B-Flow,., B-Flow. 3. 1 B Flow. 2,. 3. 3 1, 2, 3.,,. Logiq S8 GE. ₁ ₂ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B.,.,,.,,. Depth 6 cm..,,,,.,. ₁ ₃,,,. 3,.3
取扱説明書 ［F-12C］
F-12C 11.7 1 2 3 4 5 6 7 8 9 10 11 12 13 14 a bc b c d d a 15 a b cd e a b c d e 16 17 18 de a b 19 c d 20 a b a b c a d e k l m e b c d f g h i j p q r c d e f g h i j n o s 21 k l m n o p q r s a X
超音波40-5廣岡先生(膵癌)_念*.indd
1 2 3, 4, 5, 6, 7, 8, 9, 10 11,.2009 7 6,, 2.,,.,.,,,.,,,.,,,,.,,.,. a. invasive ductal carcinoma * 1 b. neuroendocrine neoplasm c. Solid-pseudopapillary neoplasm d. mass-forming tumor-producing pancreatitis
CA CA19-9 CA19-9 CA CA CA19-9 ARCHITECT i 2000SR CLIA U/mL CA % CA CA
原 著 30 22-29, 2015 CA19-9 CA19-9 CA19-9 2006 12013 6 CA19-9 32,508 37.0U/mL 790 2 CA19-9 320 CA19-9 ARCHITECT i 2000SRCLIA 0.0 37.0U/mL 8 4 1 2 18CA19-9 198.2 46.4 2,968 U/mL 5 3 2.5% CA19-9 2.5% CA19-9
42-2_26回関東甲信越地方会Pr6N_念*.indd
2014 10 18 19 TFT acoustic radiation force ARALA TI MI TI / MI TI / MI 1 2 3 4 5 1 2 3 4 5 PZT MASON 20 MRayl 20 MRayl 10 500 khz 20 MHz 1 mw 15 W 500 khz 20 MHz 100 W 60 MHz 1 2 3 4 5 4 6 6 4 1 2 3 4
S22 vol. 38 Suppl. 2013 38-3-2 38-3-3 38-3-4 38-3-5 JA 4 6 15 14:35 15:15 3 38-4-1 1 JA 38-4-2 10 38-4-3 38-4-4 5 5 6 15 15:20 16:10 3 38-5-1 1 38-5-2
vol. 38 Suppl. 2013 S21 1 6 15 11:25 12:15 4 38-1-1 38-1-2 US 38-1-3 1 38-1-4 38-1-5 2 6 15 13:40 14:30 3 38-2-1 1 38-2-2 38-2-3 CHI-Q 38-2-4 1 38-2-5 IgG4 3 6 15 13:40 14:30 4 38-3-1 S22 vol. 38 Suppl.
fiúàÕ53-3†E4_fiÁ‘W04_−Šfic.indd
Imaging Diagnosis of Sclerosing Cholangitis Toshifumi Gabata, M.D., 1) Dai Inoue, M.D., 1) Osamu Matsui, M.D., 1) Hiroki Tatsu, M.D., 2) and Yasunari Fujinaga, M.D. 3) 1) Department of Radiology, Kanazawa
Microsoft Word - stage.doc
2009 4 6 General Rules for the Study of Pancreatic Cancer April 2009 (The 6th Edition) Japan Pancreas Society - 1 - I 1 II 2 III 3 1 3 1 3 2 4 3 5 4 5 2 7 1 7 2 10 3 11 IV 12 1 12 2 12 1 12 2 12 3 12 3
抄録_46回中国地方会37-6_責.indd
46 22 9 11 Update 46-1 Gd-EOB-DTPA MRI EOB-MRI HCC dysplastic nodule DN 146 62 146 123 HCC 23 DN B hypoechoic 67 46%hyperechoic 79 54% bright loop 14% A dynamic MDCT iso density EOB-MRI 24 B CT low density
0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2
24 11 10 24 12 10 30 1 0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 23% 29% 71% 67% 6% 4% n=1525 n=1137 6% +6% -4% -2% 21% 30% 5% 35% 6% 6% 11% 40% 37% 36 172 166 371 213 226 177 54 382 704 216
10 117 5 1 121841 4 15 12 7 27 12 6 31856 8 21 1983-2 - 321899 12 21656 2 45 9 2 131816 4 91812 11 20 1887 461971 11 3 2 161703 11 13 98 3 16201700-3 - 2 35 6 7 8 9 12 13 12 481973 12 2 571982 161703 11
「諸雑公文書」整理の中間報告
30 10 3 from to 10 from to ( ) ( ) 20 20 20 20 20 35 8 39 11 41 10 41 9 41 7 43 13 41 11 42 7 42 11 41 7 42 10 4 4 8 4 30 10 ( ) ( ) 17 23 5 11 5 8 8 11 11 13 14 15 16 17 121 767 1,225 2.9 18.7 29.8 3.9
特集・総説・報告（４４行）／Ｐ０４５－０５５＿報告 日本肝移植研究会
45 Liver Transplantation in Japan in 2006 Part 2 Registry by the The Summary Four thousand three hundred thirty liver transplants have been performed as of December 31, 2006 in 59 institutions in Japan.
untitled
1 ... 3... 3... 3... 4...13...16...18...20...22 2 PTPE 3 PTPE CT Grade 2 A PTPE PTPE 4 A S 3 3 B H3,P1,N1,M1, LM0, R23 15 20gS, ptype 3, 60 x 50mm, pt4b/siurinary bladder, int, INF, ly2, v1, ppm070mm,
I
I II 1 2 3 4 5 6 7 8 9 10 11 Rp.1) 50mg 3 3 14 Rp.2) 2.5mg 2 14 Rp.1) 2.5mg 3 2 2:1 14 Rp.) 15g 1 3 28 Rp.2) 50 600mg 1 2 28 12 Rp.1) CR 20mg 1 1 1 14 Rp.2) R 200 1 2 14 Rp.3) 3 1 3 14 Rp.1) 2.5mg 0.4
電子ポスタープロ.indd
S 269 C001 Cavernous sinus dural arteriovenous fistulas with unusual posterior termination of the superficial middle cerebral vein via laterocavernous sinus: A pitfall of transvenous embolization C002
第27回日本肝胆膵外科学会_プログラム抄録集1_150507.indd
1 6 11 15:00 15:50 1 1 座 長 : 青 木 武 士 ( 昭 和 大 学 消 化 器 一 般 外 科 ) P1-1 FDG-PET 渡 辺 亮 ( 群 馬 大 学 病 態 総 合 外 科 学 ( 第 一 外 科 )) P1-2 ICG-PDE 3 荒 井 淳 一 ( 長 崎 大 学 腫 瘍 外 科 ) P1-3 ICG 菅 原 秀 一 郎 ( 山 形 大 学 医 学 部 外 科
04_学術.indd
Arts and Sciences 13D FASE MRCP The usability of Single breath-hold MRCP 33883 Key words: fast advanced spin echo FASE. magnetic resonance cholangiopancreato-graphy MRCP. single breath-hold. Summary When
Surgeons, Gastroenterologists and Oncologists) (September 23-26, 2009, Beijing) Fluorouracil intra-arterial infusion combined with systemic gemc
1. Results of salvage esophagectomy after definitive chemoradiotherapy in patients with acrcinoma of the esophagus. Watanabe M, Yoshida N, Iwagami S, Toyama E, Hayashi N, Baba H ASCO GI Gastroentestinal
北辰同窓会36号-02.21修正
36 FEB, 2011 20112 36 1 GDPOECD 1.5 0.1910 1 2 4 29 Web 40 3,500 22 9 1 22 4 3,279 6 6 6 6 22 7 28 208 1971 9 1976 3 1976 4 1977 11 1983 7 1989 5 Russell Ross 1990 5 1994 7 2002 4 2004 8 1122 9 125 8 313
; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9
32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5
天草郡市医師会第139回(臨時)代議員会
A 97 2(B A2) 4(A B3) 2 95 B 104 25(A B3) 16(B A2) 9 113 201 27 20 7 208 2 1 13 3 18 4 19 3 3 2 2 13 4 17 3 18 6 26 6 30 17 18 17 17 17 17 18 ( ) 18 ( ) 18 ( ) 18 ( ) 18 ( ) ( ) ( ) ( ) ( ) ( ) 18 ( ) (
untitled
96 E-mail mizumi@tokyo-med.ac.jpmed.ac.jp 2008.6.28 1. 2. 3. 4. vs. 5. 6. 12, 16 Poroma / vs. 1. decapitation secretion apocrine snout apical snout pinching-off fringe 2. 3. 4. 5. 6.
地域開発の事後的分析 －経済指標と社会指標による考察－
6 5 1 (1) 44 2 611 612 2-66 - 611 45 612 3 2 16 13611 2 45 1 5 23 3-6 - 613 2 3 614 615 616-68 - 61 618 619 1 611-69 - 24 51 51 2 3 2 1 4 84 1ha 55 2 II 613 2 2 16 22628 23 - - 621 15 1 23 8 2 3 2 1.8
PSCHG000.PS
ORCA FA X SA R S P.S. DNA FA X b c d c c e f c e f e f c e f c e f e b f d c c e f c e f e f ORCA ORCA CD ORCA ORCA ORCA ORCA ORCA ORCA ORCA ORCA dolphin dolphin ORCA dolphin ORCA MRT OECD
084_41-1_23四国CS6_念*.indd
2013 10 5 The forgotten chamber.,,,.1.2,,, 3,,. 4,CT,MRI,,,,,,,, fractional area change: FAC,,M tricuspid annular plane systolic excursion: TAPSE TAPSE < 16 mm., s, speckle tracking, Tei index,,,.,,,.,6,.,,,,,
抄録36-6偶_中国_責.indd
45 21 9 12 1 45-1 3D 1 5 10 1 1 12 0 13 6 2D 2 2 3D 1 14 2 63g 11cm 2 3D x 3DCT 1 3D 45-2 FIUVV 3 10 FIUVV IUFD 2 FIUVV 33 35 MRI 36 8 22 1cm FIUVV 28 IUFD 45-3 Fetal intra-abdominal umbilical vein varixfiuv
核44-4 (ガイドライン)-1
FDG-PET (2007) PET FDG PET * 2 * PET FDG PET PET/CT PET PET PET PET PET PET PET CT PET QOL PET PET PET PET 2 1. 2. 3. 4. 5. 6. 7. 8. 9. 9-1) 9-2) 9-3) FDG-PET 9-4) 9-5) A. CT B. PET/CT 9-6) MRI 9-7) 10.
第79回_プログラム.indd
Regulation of ghrelin signaling by a leptin-induced gene, negative regulatory element-binding protein, in the hypothalamic neurons. Phase I clinical trial using peptide vaccine for human vascular endothelial
cm H.11.3 P.13 2 3-106-
H11.3 H.11.3 P.4-105- cm H.11.3 P.13 2 3-106- 2 H.11.3 P.47 H.11.3 P.27 i vl1 vl2-107- 3 h vl l1 l2 1 2 0 ii H.11.3 P.49 2 iii i 2 vl1 vl2-108- H.11.3 P.50 ii 2 H.11.3 P.52 cm -109- H.11.3 P.44 S S H.11.3
取扱説明書 [F-10D]
![取扱説明書 [F-10D]](/thumbs/48/23871528.jpg "取扱説明書 [F-10D]")
F-10D 13.9 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 a bc d a b c d 17 a b cd e a b c d e 18 19 20 21 a b 22 c d 23 a b a b c d e f a b k l m n o p q r s t u v w x y g h i j c d e 24 c d e f g h i j k l
パーキンソン-本文修正済.indd
MIBG 107 LSI MIBG RI 1 SPECT MIBG 1 1 7 2-3-5 7 1-12 145 2215 1113-1-1 114 2713-1-30 5 7-1-1 6 9-1-1 401-1-11 131-2-50 10 2-15-1 2 1-2-54 43-1-1 2-10-10 1-10-1 2-1-1 1214-8 53 0166-22-8111 0166-51-3161
8 8 0
,07,,08, 8 8 0 7 8 7 8 0 0 km 7 80. 78. 00 0 8 70 8 0 8 0 8 7 8 0 0 7 0 0 7 8 0 00 0 0 7 8 7 0 0 8 0 8 7 7 7 0 j 8 80 j 7 8 8 0 0 0 8 8 8 7 0 7 7 0 8 7 7 8 7 7 80 77 7 0 0 0 7 7 0 0 0 7 0 7 8 0 8 8 7
取扱説明書 ［F-05E］
F-05E 12.11 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 a b 22 c d e 23 24 a o c d a b p q b o r s e f h i j k l m g f n a b c d e f g h 25 i j k l m n o p q r s a X b SD 26 27 28 X 29 a b c
untitled
5 10% 1 13 15cm 3 4cm 2 RS P Rb Ra S RS Ra Rb P 4 S RS CT MRI Stage 0 Stage I Stage I Stage II Ra Rb P TEM TEM ISR TEM Transanal endoscopic microsurgery 5cm 4cm 5cm TEM 1 2 3 10cm RS 6cm Ra 4cm Rb 2cm
4 15 C029 IVR angio-ct dynamic CT SSDE C030 C031 9:10~9:52 6. 核医学 1: 心大血管 肝胆膵 泌尿器 瀧 靖之 C032 3 SPECT MRI C033 FDG C034 99mTc-GSA C035 FDG-PET/CT C036 F
4 月 15 日 ( 金 ) グラム4 15 一般演題 ( 電子ポスター ) 9:10~9:45 1. 循環器 1 吉村宣彦 C001 320 CT C002 CT DES TVF MACE C003 CT 3D maximum principal strain / C004 CT C005 CT 10:00~10:35 2. 循環器 2 木村文子 C006 Landiolol C007 Singe-source
取扱説明書 [F-08D]
![取扱説明書 [F-08D]](/thumbs/48/23832237.jpg "取扱説明書 [F-08D]")
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 a bc d a b c d 17 a b cd e a b c d e 18 19 20 21 22 a c b d 23 24 a b c a b c d e f g a b j k l m n o p q r s t u v h i c d e w 25 d e f g h i j k l m n o p q r s
日本消化器外科学会雑誌第23巻第2号
Key words: carcinoma of the pancreatic head, carcinoma of the periampullary region, operative results of the pancreatic duodenal carcinoma, mode of tumor spread of the pancreatic duodenal carcinoma, factors
untitled
436 2112 12 436 2112 12 200912 12 800 900 1000 1100 1200 1300 1400 830 5F 900949 9491031 11051140 11401201 12061300 857900 10311050 10501105 13051340 13401422 5F 830 10301700 4F 403 11001150 5F 11551245
83
Candida sppmssa Haemophilus influenzae consolidation consolidation consolidation consolidation consolidation consolidation knuckle sign Westermark sign Hampton s hump Borchardt enteropathy-associated
03-07プ_一般口演_責*.indd
バブル キャビテーション 一 般 口 演 基 礎 5 月 9 日 ( 金 ) : 0-5 : 0 第 6 会 場 ( + ) 座 長 : 87- 基 -00 S6 87- 基 -00 S6 87- 基 -00 S65 87- 基 -00 S65 87- 基 -005 S66 組 織 音 響 特 性 5 月 9 日 ( 金 )5 : 50-7 : 00 第 6 会 場 ( + ) 座 長 : 87-
１ 発病のとき
A A 1944 19 60 A 1 A 20 40 2 A 4 A A 23 6 A A 13 10 100 2 2 360 A 19 2 5 A A A A A TS TS A A A 194823 6 A A 23 A 361 A 3 2 4 2 16 9 A 7 18 A A 16 4 16 3 362 A A 6 A 6 4 A A 363 A 1 A A 1 A A 364 A 1 A
89 91 93 95 97 99 101 103 105 107 109 111 113 115 H 117 119 l l 121 l l 123 125 127 129 l l l l 131 kl kl kl kl 133 135 137 139 141 143 145 147 149 151 153 155 157 159
株式会社日清製粉グループ本社 第158期中間事業報告書
C O N T E N T S...1...3...5...7...9...11...12...13...14 1 2 3 4 3.7% 5.8% 8.5% 70,100kL 81.2% 0.8% 25 20 15 10 5 0 9.18 9.54 9.74 9.62 9.65 9.71 21.04 21.97 22.44 22.23 8.54 22.31 22.45 20.41 15 12 9 6
肝粘液性嚢胞性腫瘍の1例 第74巻08号2265頁
日臨外会誌 症 74 ８ 2265 2271 2013 例 肝粘液性嚢胞性腫瘍の １ 例 国立病院機構水戸医療センター外科1 同 病理診断科2 岩 崎 健 一1 小山田 尚1 小 林 仁 存1 1 小 泉 雅 典 植 木 浜 一1 大 谷 明 夫2 患者は45歳 女性 心窩部痛を主訴に近医を受診し 胆石症の診断で当院を紹介され た 肝内側区域に径 ９ cm の わずかに造影効果を持つ多房性腫瘍を認めた
43
43 HK4001 X X 1949 Paatero 1 X MTF MTF 10 m 3,6,9mm MTF MTF 3mm,6mm,9mm MTF MTF X HK4004 200nm 950nm 600nm 760nm 850nm 960nm OH 600 900nm 600nm 800nm 44 HK4006 JPEG2000 CTF HK4007 40 X Mo Mo MTF ACR156
2003 Giemsa HE HE AE1+AE3 HBME1 HE HE Well differentiated adenocarcinoma of colon Giemsa HE HE 62 Group V HE 47 Group V Peritoneal dissemination of gastric cancer HE 51 Poorly differentiated Adenocarcinoma(por2)
56cm 1 15 1960 2 8 2 2 1 2008 1992 2 1992 2 3562mm 3773mm 2 1980 1991 2008 2007 2003 5 2 3 2003 2005 2008 2010 2005 2008 2012 2010 2012 4 7 4 5 2 1975 1994 8 2008 NPO 2 2010 3 2013 2016 3 2008 2009 14
FACT BOOK 2010J.indb
2 3 4 $440.6 41% $627.6 59% V 578,211 662,432 1,240,643 0.22 26.09 367,112 106,085 473,197 20.37 11.08 342,759 107,393 450,152-16.56 10.54 181,146 91,861 273,007 0.06 6.39 111,278 131,807 243,085 8.75
20－121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
1) Delbet P: Retrocissement du choledoque. Cholecysto-duodenostomie. Bull Mem Soc Nat Chir 50: 1144-1146, 1924 2) Wiesner RH, LaRusso NF: Clinicopathologic Features of the Syndrome of Primary Sclerosing
50-3ガイド10ポ.indd
25 7 乳房専用 PET 診療ガイドライン作成メンバー PET 1 はじめに PET 18 F-2- -2- -D- FDG 14 12 FDG-PET FDG-PET 1) T1b 0.5 cm 1.0 cm T1c 1.0 cm 2.0 cm P=0.003 1.0 cm 2) MRI FDG-PET PET 1 cm FDG FDG 1 対向型乳房専用 PET 装置 2 2 3 6) 2 4
地域開発の事後的分析 －経済指標と社会指標による考察－
47 N a N a = N N S 48 H r H r = H S / N a N N =.0079N + ( NOi NiO ) (745.86) N N NOi NiO N 4 7.0 47.8 7.9 4. 47.7 4 6.6 47 E E E 3 E = 5.64 E E 3 + 0.0445E.0074E (44.0) = 0.980E + (4.35) = 450.04 0.033E
130 中井陽介 4. 膵嚢胞性腫瘍の診療ガイドライン膵嚢胞性腫瘍に対するガイドラインとしては,IPMN/ MCNの国際診療ガイドラインとして 2006 年にいわゆる Sendai Guideline 12) が, さらに 2012 年にはFukuoka Guideline 1) として改訂が行われ
埼玉医科大学雑誌第 43 巻第 2 号平成 29 年 3 月 129 総説 膵嚢胞性腫瘍ガイドラインをめぐって 超音波内視鏡診断 治療の役割 中井陽介 東京大学消化器内科 1. はじめに 近年, 日常臨床において膵嚢胞性病変に遭遇する機会が増えている. 特に健康診断 人間ドックで行われる画像検査あるいは他疾患の精査 経過観察で行われる画像検査などによって偶発的に診断される無症候性膵嚢胞性病変は増加の一途をたどっている.
15 7 26 1,276 3,800 1 16 15 1 2 3 4 2
1 15 7 26 1,276 3,800 1 16 15 1 2 3 4 2 JA 3 4 2 1 3 2001 1981 6 10% 10 30% 1 2 JA JA 2 4 JA 2 1 2 1 2 1 2 1 2 1 2 7 5 1 1 1 3 1 6 1 1 2 2 1 7 2 3 3 53 1 2000 30 8 250 53 435 20 35 3 1 8 2 4 3 2 2 232
EX-word_Library_JA
JA 2 3 4 5 14 7 1 2 6 3 1 2 7 3 8 27 1 2 3 1 2 3 9 1 2 3 1 2 3 10 12 13 14 11 1 12 1 2 13 1 2 3 25 14 1 2 3 25 15 1 2 3 25 16 1 2 3 25 17 1 2 3 25 18 1 2 3 4 25 19 1 2 3 4 25 20 1 2 21 3 4 25 22 1 2 3
324.pdf
50 50 10 30 11 26 12 27 14 16 27 18 20 21 22 22 22 22 23 24 24 1 No.324 JA 2 85 69 20 12 81 18 12 22 93 10 31 3 50 50 30 30 50 22 27 27 10 16 14 52 10 62 15 64 25 24 50 4 25 23 27 5 10 11 25 6 11 49 10
『こみの株式会社』の実践
2003 . JA JA A JA 811 2005/8/11 1003 452 10 960 28 2005/8/11 1003 452 6 120 29 2005/8/11 2003 151 10 420 33 2005/8/11 2003 211 3 180 31 2005/8/11 2003 211 3 150 32 827 400 5 80 221 2005/6/25 900 3 300
島根大チュートリアル学習2011
2011 Bench pathologist bench pathologist 2000 130 60 WHO UICC 1 34 6500 1-2% 1960 dysplasia squamous intraepithelial neoplasia SIN CIN cervical intraepithelial neoplasia WHO 1992 WHO 3 2005 basal cell
_06.indd
30, 35-39, 2010 0.15% 1 C 40 20 1 cm 5 mm WBC 9,400, RBC 259 10 4, Hb 8.5 g/dl, Ht 25.5%, Plt 29 10 4, BUN 116 mg/dl, Cr 7.9 mg/dl, 125 mg/dl, HbA1c 4.3%, ft3 1.97 pg/ml, ft4 1.05 ng/dl, TSH 1.09 μiu/ml,
i ii ( ) ( ) ( ) 462,891 525,032 502,164 230,636 CD CD 1 1 2 2 3 3 4 4 5 5 6 6 7 7 8 8 9 9 10 10 11 10 12 11 13 11 14 12 15 12 16 13 16 14 17 15 18 15 18 16 19 17 20 17 18 19
Major Histocompatibility Complex 2018; 25 (2): 抄録集 2 HLA A 3 128
Major Histocompatibility Complex 2018; 25 (: 128 138 抄録集 2018 4 14 A 3 128 MHC 2018; 25 ( HLA 2013 10.5 10 8 12 10 8 2016 CD34 + HLA NC 10 8 CD34 + CD34 + 10 6 NC10.5 2013.Apr 2014.Mar NC11 2014.Apr 2016.Jun
PSCHG000.PS
FA X P.S. ? CT FCR VT VT VT EBM IT b cd e e f f f f f f f f f f f f f f f f f f f f f f f f f f f f OB) GDPGDP ACLS b c d Ambitious :: F FAX CT CT genericnam e JA AZM JA AZM JA-AZM
FR 34 316 13 303 54
FR 34 316 13 303 54 23 ( 1 14 ) ( 3 10 ) 8/4 8/ 100% 8 22 7 12 1 9 8 45 25 28 17 19 14 3/1 6/27 5000 8/4 12/2930 1 66 45 43 35 49 25 22 20 23 21 17 13 20 6 1 8 52 1 50 4 11 49 3/4/5 75 6/7/8 46 9/10/11
(%) 6. 5. 4. 3. 2. 1.. -1. -2. -3. -4. -5. 21/1-3 22/1-3 23/1-3 24/1-3 18, 17, 16, 15, 1 92 84 76 14, 68 13, 6 12, 52 11, 44 1, 9, 8, 7, 36 28 2 22/1 22/7 23/1 23/7 ( 1 FACT BOOK 24 2 14, 12, 1, 8, 6,
![かんたん操作ガイド[arrows M02]](/thumbs/39/20071242.jpg "かんたん操作ガイド[arrows M02]")
![かんたん操作ガイド[arrows RM02]](/thumbs/39/20475147.jpg "かんたん操作ガイド[arrows RM02]")
